Puma Biotechnology, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 10.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 544.08M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Details
| Name | Puma Biotechnology, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 179 |
| Founded | 2010 |
| Ceo | Alan Auerbach |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US74587V1070 |
| Cusip | 74587V107 |
| Cik | 0001401667 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer and Secretary |
| Maximo F. Nougues | Chief Financial Officer and Principal Accounting Officer |
| Douglas Hunt B.Sc., FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance and Law Officer |
| Gordon G. Esplin | Chief Accounting Officer |
| Mariann Ohanesian | Senior Director of Investor Relations |
| Heather Blaber | Senior Vice President of Marketing |
| Roger L. Storms | Senior Vice President of Sales |
| Pamela Wilson BA | Senior Vice President of Clinical Operations |
| Dr. Petra Rietschel | Senior Vice President of Clinical Development |
| Kenneth Wiehe | Senior Vice President of Supply Chain and Manufacturing |
Contact
| Address | 10880 Wilshire Boulevard, Suite 1700, Los Angeles, California 90024, United States |
| Phone | 424 248 6500 |
| Website | https://www.pumabiotechnology.com |